Related Experiment Video

Updated: Feb 15, 2026

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
07:11

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling

Published on: February 5, 2019

9.7K

[TREATMENT WITH INO OF INFANTS WITH PPHN.]

P Radulova, L Vakrilova, B Slancheva

    Akusherstvo I Ginekologiia
    |January 26, 2018
    PubMed

    Insights

    Persistent pulmonary hypertension of newborns (PPHN) is serious, but inhaled nitric oxide (iNO) offers a promising treatment. This study shows iNO rapidly stabilized hemodynamics in infants with PPHN, leading to survival without side effects.

    Area of Science:

    • Neonatology
    • Pediatric Cardiology
    • Pulmonary Medicine

    Background:

    • Persistent pulmonary hypertension of newborns (PPHN) is a critical condition characterized by elevated pulmonary vascular resistance.
    • Current PPHN treatments are often complex and yield limited efficacy.
    • PPHN involves a persistent right-to-left shunt through the foramen ovale and ductus arteriosus.

    Purpose of the Study:

    • To evaluate the efficacy and safety of inhaled nitric oxide (iNO) in treating infants diagnosed with PPHN.
    • To assess the impact of iNO on hemodynamic stabilization and neurodevelopmental outcomes in PPHN patients.

    Main Methods:

    • Case series involving six infants diagnosed with PPHN.
    • Treatment administered included inhaled nitric oxide (iNO).
    • Clinical and hemodynamic parameters were monitored during treatment.

    Main Results:

    • Inhaled nitric oxide (iNO) demonstrated a rapid clinical effect in all treated infants.
    • Hemodynamic stabilization was achieved following iNO administration.
    • All infants survived the PPHN episode without reported side effects.

    Conclusions:

    • Inhaled nitric oxide (iNO) is an effective therapeutic option for PPHN.
    • iNO treatment in infants with PPHN leads to improved survival and neurodevelopmental outcomes.
    • iNO represents a vital component of pathogenetic treatment for PPHN.

    More Related Videos

    P50 Sensory Gating in Infants12:55

    P50 Sensory Gating in Infants

    Published on: December 26, 2013

    9.6K
    Author Spotlight: Marmoset Research - Scope and Challenges04:52

    Author Spotlight: Marmoset Research - Scope and Challenges

    Published on: June 9, 2023

    2.7K

    Related Concept Videos

    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    335
    Open Angle Glaucoma: Treatment01:27

    Open Angle Glaucoma: Treatment

    In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
    Drugs such as carbonic anhydrase inhibitors, α2- and...
    1.0K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
    1.2K
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    987
    Anticholinesterase Agents: Poisoning and Treatment01:26

    Anticholinesterase Agents: Poisoning and Treatment

    Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
    Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
    1.7K